New York State Common Retirement Fund Trims Position in Natera, Inc. (NASDAQ:NTRA)

New York State Common Retirement Fund trimmed its position in Natera, Inc. (NASDAQ:NTRA) by 10.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 72,829 shares of the medical research company’s stock after selling 8,864 shares during the period. New York State Common Retirement Fund’s holdings in Natera were worth $11,529,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Creative Planning lifted its stake in shares of Natera by 18.3% in the 3rd quarter. Creative Planning now owns 5,833 shares of the medical research company’s stock worth $740,000 after purchasing an additional 904 shares during the period. Private Advisor Group LLC raised its position in Natera by 5.2% in the third quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock worth $346,000 after acquiring an additional 135 shares during the period. International Assets Investment Management LLC raised its position in Natera by 9,755.3% in the third quarter. International Assets Investment Management LLC now owns 14,980 shares of the medical research company’s stock worth $1,902,000 after acquiring an additional 14,828 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Natera by 17.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 10,858 shares of the medical research company’s stock worth $1,378,000 after acquiring an additional 1,640 shares during the last quarter. Finally, Pallas Capital Advisors LLC grew its position in shares of Natera by 53.7% during the 3rd quarter. Pallas Capital Advisors LLC now owns 6,469 shares of the medical research company’s stock valued at $771,000 after acquiring an additional 2,260 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. StockNews.com cut Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Barclays began coverage on Natera in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Guggenheim raised their target price on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. Finally, TD Cowen upped their price target on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $170.94.

Insider Buying and Selling at Natera

In related news, insider John Fesko sold 663 shares of the firm’s stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the transaction, the insider now directly owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 78,553 shares of the company’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the sale, the chief executive officer now directly owns 267,629 shares in the company, valued at approximately $44,150,756.13. The trade was a 22.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 295,772 shares of company stock worth $49,741,699 in the last quarter. 7.60% of the stock is owned by corporate insiders.

Natera Trading Down 2.4 %

Shares of NTRA stock opened at $158.37 on Tuesday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $20.91 billion, a price-to-earnings ratio of -89.98 and a beta of 1.66. Natera, Inc. has a 12-month low of $70.71 and a 12-month high of $183.00. The stock’s 50-day moving average price is $167.73 and its 200-day moving average price is $146.21.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.